Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like Bay Area's Guardant Health Just Snagged $360 Million to Create Cancer Blood Tests May 10, 2017 EXACT Sciences To Host Fourth-Quarter, Full-Year 2016 Results Webcast And Call January 25, 2017 VIDA Diagnostics Enriches Pulmonary Suite To Include Advanced COPD And Asthma Analysis September 10, 2017
VIDA Diagnostics Enriches Pulmonary Suite To Include Advanced COPD And Asthma Analysis September 10, 2017
